中文

News Center

Preview | Doer Biologics' Phase II Clinical Results of DR10624 for the Treatment of MASLD/MASH Selected for AASLD 2026 Late-Breaking Abstract (LBA) and to Be Presented as an Oral Presentation

2026/10/21

Read more

China IND Approval Granted for Doer Biologics' DR30206 for Injection for a New Indication, Intended for Consolidation Therapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent/Sequential Chemo

2026/10/16

Read more

China IND Approval Granted for Doer Biologics' DR30206 for Injection in Combination with Standard Chemotherapy for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

2026/10/13

Read more

First Patient Dosed in Phase II Clinical Study of Doer Biologics' DR10624 for the Treatment of Moderate Hypertriglyceridemia Complicated with Diabetic Kidney Disease

2026/10/09

Read more

Doer Biologics Completes First Patient Enrollment in Two Phase 3 Clinical Trials of DR10624 for Severe Hypertriglyceridemia

2026/09/08

Read more

Doer Biologics Announces First Subject Dosed in Phase Ib Trial of DR30206 in Combination with Standard Chemotherapy for NSCLC

2026/09/04

Read more

Targeting the Heart Failure Blue Ocean, Huadong Medicine's DR10624 Selected for National Science and Technology Major Project, Multi-Indication Strategic Blueprint Emerges

2026/08/13

Read more

DR10624 Selected for the 2026 National Science and Technology Major Project "Innovative Drug Development for Heart Failure" – Project Kick-off Meeting Successfully Held

2026/08/13

Read more

Pharma Sources Exclusive: Doer Biologics COO Dr. Fang Yongliang Unveils the Therapeutic Potential and Clinical Development of Triple Agonist DR10624

2026/07/23

Read more

Doer Biologics' Global First-in-Class Triple Agonist DR10624 Receives China IND Approval for HFpEF/HFrEF

2026/07/14

Read more